# Bevacizumab Treatment For Type 1 ROP

> **NCT04634578** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jaeb Center for Health Research** · enrollment: 77 (actual)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04634578
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04634578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04634578, "Bevacizumab Treatment For Type 1 ROP". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04634578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*